Resource utilisation and cost of ambulatory HIV care in a regional HIV centre in Ireland: A micro-costing study

BMC Health Services Research

Volumn 15, Issue 1, 2015, Pages

  Brennan, Aline ^a   Jackson, Arthur ^b   Horgan, Mary ^c   Bergin, Colm J ^d   Browne, John P ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Department of Medicine National University of Ireland Cork   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d ST JAMES S HOSPITAL   (Ireland)

Author keywords

Ambulatory care; Cost; Healthcare utilisation; HIV; Micro costing; Outpatient care

Indexed keywords

ADULT; AGE; AGED; AMBULATORY CARE; ECONOMICS; FEMALE; HEALTH CARE DELIVERY; HIV INFECTIONS; HUMAN; IRELAND; MALE; MIDDLE AGED; OUTPATIENT DEPARTMENT; SEX DIFFERENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMBULATORY CARE; AMBULATORY CARE FACILITIES; DELIVERY OF HEALTH CARE; FEMALE; HIV INFECTIONS; HUMANS; IRELAND; MALE; MIDDLE AGED; SEX FACTORS; YOUNG ADULT;

EID: 84927514837     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-015-0816-1     Document Type: Article

References (42)

1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525-33.
2. van Sighem AI, Gras LJ, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS (London, England). 2010;24:1527-35.
3. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (London, England). 2012;26:335-43.
4. High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH office of AIDS research by the HIV and aging working group. J Acquir Immune Defic Syndr. 2012;60:S1-18.
5. HIV and ageing - a special supplement to the UNAIDS report on the global AIDS epidemic 2013. Geneva: UNAIDS; 2013.
6. HIV in Ireland 2012 Report. Dublin: Health Protection Surveillance Centre; 2013.
7. Tuite H, Horgan M, Mallon P, McConkey S, Mooka B, Mulcahy F, et al. Antiretroviral treatment and viral load responses in HIV-infected patients accessing specialist care in Ireland. London: 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2012.
8. Blair JM, Fagan JL, Frazier EL, Do A, Bradley H, Valverde EE, et al. Behavioral and clinical characteristics of persons receiving medical care for HIV infection - medical monitoring project, United States, 2009. Morb Mortal Wkly Rep Surveill Summ (Washington, DC: 2002). 2014;63 Suppl 5:1-22.
9. HIV in the United Kingdom: 2012 Report. London: Health Protection Agency; 2012.
10. Ambrosioni J, Nicolas D, Aguero F, Manzardo C, Miro JM. HIV treatment outcomes in Europe and North America: what can we learn from the differences? Expert Rev Anti Infect Ther. 2014;12(5):523-6.
11. Beck EJ, Avila C, Gerbase S, Harling G, De Lay P. Counting the cost of not costing HIV health facilities accurately pay now, or pay more later. Pharmacoecon. 2012;30(10):887-902.
12. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of healthcare programmes. 3rd ed. Oxford: Oxford University Press; 2005.
13. Tan SS, Rutten FF, van Ineveld BM, Redekop WK, Hakkaart-van Roijen L. Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ. 2009;10(1):39-45.
14. Wordsworth S, Ludbrook A, Caskey F, Macleod A. Collecting unit cost data in multicentre studies. Creating comparable methods. Eur J Health Econ. 2005;6(1):38-44.
15. Heerey A, McGowan B, Ryan M, Barry M. Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation. Expert Rev Pharmacoecon Outcomes Res. 2002;2:29-33.
16. Ryan M. A study of the impact of highly active antiretroviral therapy on the pharmacoepidemiology and pharmacoeconomics of HIV infection. Dublin: University of Dublin, Trinity College; 2000.
17. CPA01 Consumer Price Index by Year, Commodity Group and Statistic (1975-2013) [ www.cso.ie ]
18. Department of Health and Children. Money Follows the Patient - Policy Paper on Hospital Financing. 2013.
19. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012;13 Suppl 2:1-85.
20. European AIDS Clinical Society Guidelines Version 6.0 October 2011. Brussels: European AIDS Clinical Society; 2011.
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. Department of Health and Human Services. 2012. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 6 June 2012.
22. The Public Spending Code: E. Technical References E.01 Calculation of Staff Costs [ http://publicspendingcode.per.gov.ie/e-01-calculation-of-staff-costs/ ]
23. Framework agreement between the Irish Pharmaceutical Healthcare Association LTD and the Department of Health and the Health Service Executive on the supply terms, conditions and prices of medicines [ http://www.hse.ie/eng/about/Who/cpu/IPHA-APMI-Agreements.html ]
24. Framework agreement between the Association of Pharmaceutical Mnufactureres of Ireland and the Department of Health and the Health Service Executive on the supply terms, conditions and prices of generic medicines [ http://www.hse.ie/eng/about/Who/cpu/APMI-Agreement-2012.pdf ]
25. Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897-916.
26. Glick HA, Doshi JA, Sonnad SA, Polsky D. Economic evaluation in clinical trials. 2nd ed. Oxford: Oxford University Press; 2015.
27. Ghatnekar O, Hjortsberg C, Gisslén M, Lindbäck S, Löthgren M. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden. Pharmacoecon. 2010;28 Suppl 1:49-57.
28. Mostardt S, Hanhoff N, Wasem J, Goetzenich A, Schewe K, Wolf E, et al. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNA K3A study. Eur J Health Econ. 2013;14(5):799-808.
29. Lopez-Bastida J, Oliva-Moreno J, Perestelo-Perez L, Serrano-Aguilar P. The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain. BMC Health Serv Res. 2009;9:55.
30. Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS. 2004;18(18):2411-8.
31. Krentz H, Gill M. Increased costs of HIV care associated with aging in an HIV-infected population. HIV Med. 2015;16(1):38-47.
32. Rizzardini G, Restelli U, Bonfanti P, Porazzi E, Ricci E, Casartelli L, et al. The cost of HIV disease in Northern Italy: the payer's perspective. J Acquir Immune Defic Syndr. 2011;57(3):211-7.
33. Gardner EM, Maravi ME, Rietmeijer C, Davidson AJ, Burman WJ. The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy. 2008;6(2-3):145-55.
34. Yazdanpanah Y. Costs associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(4):558-61.
35. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
36. Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2):84-92.
37. Gazzard B, Moecklinghoff C, Hill A. New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. ClinicoEconomics Outcomes Res. 2012;4:193-200.
38. Hill A, Hill T, Jose S, Pozniak A. Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018. J Int AIDS Soc. 2014;17(4 Suppl 3):19497.
39. Brennan A, Morley D, O'Leary AC, Bergin CJ, Horgan M. Determinants of HIV outpatient service utilization: a systematic review. AIDS Behav. 2015;19(1):104-19.
40. Krentz HB, Gill MJ. The direct medical costs of late presentation (<350/mm) of HIV infection over a 15-year period. AIDS Res Treat. 2012;2012:757135.
41. Brennan A, Jackson A, Browne J, Bergin C, Horgan M. Use of hospital services by HIV patients, 2012. Value Health. 2014;17(7):A684.
42. Gillespie P, O'Neill C, Avalos G, O'Reilly M, Dunne F, Collaborators AD. The cost of universal screening for gestational diabetes mellitus in Ireland. Diabet Med. 2011;28(8):912-8.